Patent injunction in pharma disputes may be refused where disclosure is incomplete, validity is credibly challenged, and public access weighs heavily.
In a patent infringement suit seeking ad interim injunction, full disclosure of the complete specification, relevant x-ray diffraction data, and pending related applications was required to establish a prima facie case; non-disclosure of material particulars defeated interim relief. The Court treated section 3(d) of the Patents Act, 1970 as an anti-evergreening provision for pharmaceutical inventions and found a credible challenge where enhanced efficacy and novelty were seriously in issue, making the patent vulnerable at the interlocutory stage. Public interest in access to an affordable life-saving medicine was also relevant and, on the balance of equities, justified refusal of interim injunction.
Issues: (i) whether the plaintiffs had made a prima facie case for interlocutory injunction in a patent infringement suit where the complete specification, x-ray diffraction data, and pending related patent applications were not fully disclosed; (ii) whether the defendant had raised a credible challenge to the validity of the patent under the Patents Act, 1970, particularly in the context of section 3(d), novelty, obviousness, and enhanced efficacy; and (iii) whether public interest in access to an affordable life-saving drug could justify refusal of interim injunction despite the asserted patent rights.
Issue (i): Whether the plaintiffs had made a prima facie case for interlocutory injunction in a patent infringement suit where the complete specification, x-ray diffraction data, and pending related patent applications were not fully disclosed.
Analysis: In an application for ad interim injunction in a patent suit, the plaintiff was required to disclose the complete specification of the product said to be protected, the relevant x-ray diffraction data in the case of a pharmaceutical drug, and any other pending applications for derivatives or forms of the same product. The non-disclosure of the pending polymorph B applications, coupled with the absence of full technical particulars, prevented a clear finding that the patent held by the plaintiffs covered the tablet form marketed as Tarceva. Such suppression of material facts went directly to the existence of a prima facie case.
Conclusion: The plaintiffs failed to establish a prima facie case and were not entitled to interim injunction on this ground.
Issue (ii): Whether the defendant had raised a credible challenge to the validity of the patent under the Patents Act, 1970, particularly in the context of section 3(d), novelty, obviousness, and enhanced efficacy.
Analysis: Section 3(d) was treated as a substantive anti-evergreening provision, especially for pharmaceutical products, requiring demonstration that a derivative or new form differed significantly in properties with regard to efficacy. The defendant's challenge was held to be more than credible because the material before the Court showed a serious triable question on whether the claimed product was merely a different form of a known substance and whether enhanced therapeutic efficacy had in fact been shown. The patent grant was not treated as conclusive of validity at the interlocutory stage, and the challenge was viewed as sufficient to render the patent vulnerable.
Conclusion: The defendant successfully raised a credible challenge to the validity of the patent, and the patent was held vulnerable to challenge.
Issue (iii): Whether public interest in access to an affordable life-saving drug could justify refusal of interim injunction despite the asserted patent rights.
Analysis: The Court held that public interest is relevant within the Patents Act, 1970 itself, including the statutory emphasis on affordable availability and public health. Given the drug's character as a life-saving cancer medicine, its limited availability and high price, and the risk that an injunction would reduce access to a generic alternative, the balance of equities favoured the defendant. The public interest in wider access to the medicine outweighed the claim for interim restraint by the patent holder at this stage.
Conclusion: Public interest justified refusal of interim injunction.
Final Conclusion: The appeal failed because the plaintiffs did not show a sufficient basis for interim protection, the defendant's validity challenge was credible, and the public interest in access to the medicine weighed against injunctive relief.
Ratio Decidendi: In a patent infringement suit seeking ad interim injunction, the plaintiff must make full disclosure of the patent specification and all materially relevant related applications, and an interlocutory injunction may be refused where the defendant raises a credible challenge showing the patent is vulnerable, especially in relation to pharmaceutical inventions governed by section 3(d) and the public interest in access to life-saving drugs.
TaxTMI 
AI Drafter ✕
TaxTMI 
